One of the major highlights this year was the launch of the new software version, RetinaLyze 4.0. This upgrade has been a game-changer for eye specialists, offering an improved workflow that makes it easier and faster to analyze retinal images. The updated software not only streamlines the analysis process but also integrates more seamlessly with existing systems, ensuring that specialists can focus on what truly matters—patient care.
The enhancements in this version include more intuitive user interfaces and more robust integration capabilities with electronic health records (EHR). This development aligns with our mission to simplify and accelerate the process of diagnosing eye conditions, thereby enabling more timely interventions.
In addition to the software upgrade, we’ve also launched an innovative tool—the RetinaLyze Advanced Glaucoma Progression AI, featuring the Glaucoma Index of Progression (GIP). This analytical tool is designed to measure changes in glaucoma status with notable stability over time. While GIP may offer slightly less precision than the Globin Discriminant Function (GDF) in determining the exact boundary of normalcy, it excels in tracking the progression or regression of a patient’s condition.
What sets GIP apart is its reduced reliance on deep learning algorithms, making it particularly valuable for longitudinal studies where consistency is key. It’s essential to keep in mind that “normality” in medical terms is statistically defined, meaning a patient’s condition could deteriorate even if their metrics remain within a so-called normal range. The RetinaLyze Advanced Glaucoma Progression AI helps in capturing these nuances, providing a more comprehensive understanding of glaucoma progression.
2024 has also marked RetinaLyze’s entry into the Brazilian market with our distribution partner Avita/NCS Healthcare. This expansion is a significant milestone, allowing us to bring our innovative eye care solutions to a broader audience. Brazil’s healthcare system and eye care professionals can now benefit from the cutting-edge technology that RetinaLyze offers, contributing to better eye health outcomes across the region.
In line with our commitment to continuous improvement, RetinaLyze OCT has been updated with a more refined algorithm, designed to further enhance diagnostic accuracy. One of the key features of this update is its ability to automatically crop away the disc area from wide scans, significantly reducing the likelihood of false positives during analysis. This improvement is especially beneficial in ensuring that retinal conditions are detected with greater precision, allowing eye care professionals to make more confident decisions.
Moreover, the updated algorithm is more resilient to suboptimal scan quality. By detecting artefacts within the scans, RetinaLyze OCT can effectively mitigate the risk of false negatives. This ensures that even when the scan/image quality is compromised, the system maintains its reliability, providing specialists with consistent and trustworthy results.
Finally, as we look to the future, one of the exciting developments on the horizon is the redesign of our PDF reports. We understand that clear, concise, and aesthetically pleasing reports are vital for both specialists and patients. The upcoming redesign will focus on improving the visual presentation of data, making it even easier to interpret the results and take the necessary actions.
The year 2024 has been one of growth, innovation, and expansion for RetinaLyze. From the launch of RetinaLyze 4.0 to the introduction of the Advanced Glaucoma Progression AI, our goal has been to empower eye care professionals with the tools they need to deliver exceptional care. As we continue to innovate, we’re excited about what the future holds and remain committed to advancing eye health globally.
Stay tuned for more updates as we continue to push the boundaries of what’s possible in eye care technology.
RetinaLyze OCT is powered by Altris.ai.
